MBX Biosciences (MBX) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xencor (XNCR) has outperformed MBX Biosciences (MBX) over the past year, gaining 109.6% versus a gain of 83.0%. Xencor is the larger company by market cap ($2.50 billion vs $2.46 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | XNCR |
|---|---|---|
| Share price | $49.55 | $33.26 |
| Market cap | $2.46B | $2.50B |
| 1-day change | -7.23% | -2.21% |
| YTD return | +57.10% | +117.24% |
| 1-year return | +82.98% | +109.58% |
| 5-year return | — | -6.15% |
| EPS (TTM) | $-3.03 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | $-87.00M | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $72.64 | $40.60 |
| 52-week low | $26.14 | $10.38 |
| Distance from 52-week high | -31.79% | -18.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +91.91% | +27.78% |
| Average volume | 532.80K | 1.54M |
| Shares outstanding | 49.66M | 75.04M |
| Employees | 63 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed MBX by 26.6 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
MBX vs XNCR FAQ
Which is bigger, MBX Biosciences or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.46B for MBX Biosciences (MBX).
Which stock has performed better over the past year, MBX or XNCR?
XNCR returned +109.58% over the past 12 months, compared with +82.98% for MBX (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.